Chronic kidney disease after orthotopic liver transplantation in recipients receiving tacrolimus

Clinical Nephrology

Volumn 75, Issue 2, 2011, Pages 150-157

  Garces, G ^a   Contreras, G ^b   Carvalho, D ^b   Jaraba, I M ^b   Carvalho, C ^c   Tzakis, A ^b   Moon, J ^b   Ratnam, K ^a   Roth, D ^b  

^a Denver Nephrology   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

Chronic kidney disease; Hepatitis C; Liver transplantation; Survival; Tacrolimus

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LIVER DISEASE; LIVER TRANSPLANTATION; MALE; MORTALITY; ORGAN TRANSPLANTATION; PROTHROMBIN TIME; RENAL REPLACEMENT THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; CALCINEURIN; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FLORIDA; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TACROLIMUS; TIME FACTORS;

EID: 79251509276     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP75150     Document Type: Article

References (28)

1. Cohen DJ, Loertscher R, Rubin MF, Tilney NL, Carpenter CB, Strom TB. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med. 1984; 101: 667-682.
2. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine- associated chronic nephropathy. N Engl J Med. 1984; 311: 699-705.
3. Platz KP, Mueller AR, Blumhardt G. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation. 1994; 58: 170-178.
4. Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. Mayo Clin Proc. 1994; 69: 105-111.
5. Powell-Jackson PR, Young B, Calne RY, Williams R. Nephrotoxicity of parenterally administered cyclosporine after orthotopic liver transplantation. Transplantation. 1983; 36: 505-508.
6. Shulman H, Striker G, Deeg, HJ, Kennedy M, Storb R, Thomas ED. Nephrotoxicity of cyclosporine after allogeneic marrow transplantation. N Engl J Med. 1981; 305: 1392-1395.
7. Wilkinson AH, Cohen DJ. Renal failure in the recipients of nonrenal solid organ transplants. J Am Soc Nephrol. 1999; 10: 1136-1144.
8. Fraley DS, Burr R, Bernardini J, Angus D, Kramer DJ, Johnson JP. Impact of acute renal failure on mortality in end-stage liver disease with or without transplantation. Kidney Int. 1998; 54: 518-524.
9. Contreras G, Garces G, Quartin A, Cely C, Lagatta M, Barreto G, Roth D,Gomez E. An epidemiologic study of early renal replacement therapy after orthotopic liver transplantation. J Am Soc Nephrol. 2002; 13: 228-233.
10. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003; 349: 931-940.
11. Davis GL. Chronic hepatitis C and liver transplantation. Rev Gastroenterol Disord. 2004; 4: 7-17.
12. Fisher NC, Nightingale PG, Gunson B, Lipkin G, Neuberger J. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation. 1998; 66: 59-66.
13. O'Riordan A, Wong V, McCormick A, Hegarty J, Watson A. Chronic kidney disease post-liver transplantation. Nephrol Dial Transplant. 2006; 21: 2630-2636.
14. Gonwa TA, Klintmalm GB, Levy M, Jennings L, Goldstein R, Husberg B. Impact of pretransplant renal function on survival after liver transplantation. Transplantation. 1995; 59: 361-365.
15. Gonwa, TA, Mai ML, Melton L, Hays S, Goldstein R, Levy M, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2001; 72: 1934-1939.
16. Levey AS, Greene T, Kusek JW, Beck GJ, MDRD Study Group. Asimplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000; 11: 155.
17. Porayko MK, Gonwa TA, Klintman GB, Wiesner RH. Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. U.S. Multicenter Liver Study Group. Transplant Proc. 1995; 27: 1114-1116.
18. Pillebout E, Nochy D, Hill G, Conti F, Antoine C, Calmus Y, Glotz D. Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant. 2005; 5: 1120-1129.
19. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome - experience in 300 patients. Transplantation. 1991; 51: 428-430.
20. Schlitt HJ, Barkmann A, Boker KH, Schmidt HH, Emmanouilidis N, Rosenau J, Bahr MJ, Tusch G, Manns MP, Nashan, B, Klempnauer J. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet. 2001; 357: 587-591.
21. Lam P, Yoshida A, Brown K, Abouljoud M, Bajjoka I, Dagher F, Moonka D. The efficacy and limitations of sirolimus conversion in liver transplant patientswho develop renal dysfunction on calcineurin inhibitors. Dig Dis Sci. 2004; 49: 1029-1035.
22. Forman LM, Lewis JD, Berlin J, Feldman H, Lucey M. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002; 122: 889-896.
23. Gane E, Portmann B, Naoumov N, Smith H, Underhill J, Donaldson P, Maertens G, Williams R. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996; 334: 815-820. (Pubitemid 26099603)
24. Ghobrial R, Steadman R, Gornbein J, Lassman C, Holt C, Chen P, Farmer D, Yersiz H, Danino N, Collison E, Baquarizo A, Han S, Saab S, Goldstein L, Donovan J, Esrason K, Busohil R.Aten year experience of liver transplantation for hepatitis C: Analysis of factors determining outcome in over 500 patients. Ann Surg. 2001; 234: 384-394.
25. Samuel D, Feray C. Recurrent hepatitis C after liver transplantation: Clinical and therapeutic issues. J Viral Hepat. 2000; 7: 87-92.
26. Wright TL, Donegan E, Hsu H, Ferrell L, Lake J, Kim M, Combs C, Fennessy S, Robert J, Ascher N. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology. 1992; 103: 317-322.
27. Teixeira R, Pastacaldi S, Papatheodoridis G, Burroughs A. Recurrent hepatitis C after liver transplantation. J Med Virol. 2000; 61: 443-454.
28. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmaln GB. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transplantation. 2004; 10: 301-309.